HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Inhibikase Therapeutics but lowered the price target from $15 to $5.
October 14, 2024 | 5:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Inhibikase Therapeutics but significantly lowered the price target from $15 to $5, indicating a more cautious outlook.
The significant reduction in the price target from $15 to $5 suggests a more cautious outlook on the stock's potential, which could lead to a negative short-term impact on the stock price despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100